Market Overview

Amyris Delivers Another Quarter of Profitable Growth while Executing well on Strategic Agenda

Share:
  • Q2 2018 GAAP revenue of $24.8 million, compared with GAAP revenue of $25.7 million for Q2 2017. Second-quarter revenue of $24.8 million compared with the same period in 2017 of $21.7 million when adjusted for the low margin product sales on contracts assigned to DSM. This reflects 15% growth on an absolute basis.
  • Q2 2018 GAAP net income attributable to common shareholders of $2.6 million, or $0.05 per basic and $(0.32) per diluted share, compared with a net loss of $10.3 million, or $0.44 per basic and diluted share for Q2 2017.
  • Q2 2018 Adjusted gross margin of $20.9 million, or 84% of revenue, compared to Q2 of 2017 of $8.0 million, or 31%.

EMERYVILLE, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (NASDAQ:AMRS), the industrial bioscience company, today announced preliminary unaudited financial results for the second quarter ended June 30, 2018.

"Overall, we are pleased with our second quarter results as demonstration that our focus on profitable growth is yielding results. Our core products are delivering better than expected growth at gross margin levels in excess of plan, and we've significantly reduced our cost infrastructure. As importantly, we have advanced a meaningful number of strategic collaborations and partnerships, establishing a very solid base from which to accelerate growth into the second half of the year," said John Melo, Amyris President & CEO. "Several of these discussions involve somewhat complex negotiations with our top prospective partners in China, including one significant partnership we anticipated closing in the second quarter, yet now expect to close in the second half. Despite this near term push, I want to be clear that we are gaining significant traction in the Chinese market, and our expected partnerships with some of China's leading companies now represent a much more significant portion of our collaboration portfolio. We are managing the signing of our major contracts carefully to maximize shareholder value and to ensure we are working on the best products with the best partner."

Continued Melo, "Our natural sweetener product opportunity gained significant traction during the second quarter and we have the customers in place to sell all of our supply over the next three years. We anticipate announcing these customers later this year. We are confident that closing on new collaborations, together with expected shipments of zero-calorie sugar and our existing pipeline of business, will propel us through a very strong second half to close out a solid year."

Key Highlights

Other key recent operating and development highlights included:

  • Announced plans to partner with BGI, one of the world's largest genomics companies. The companies intend to apply their synthetic biology platforms in a new joint venture to discover, develop and commercialize human microbiome-targeting health and nutrition products in Greater China.
     
  • Currently in discussions for a total of three significant agreements in the China market including one that had been expected to close in Q2 2018 and now on track for second half 2018. Have commitments for zero-calorie sugar product to sell all of supply over next three years to 4 customers.
     
  • Signed Universidade Católica Portuguesa (UCP) Porto Campus and AICEP Portugal Global (AICEP) agreement valued up to $50 million including investment funding and incentives allotted across parties involved. Amyris believes this is the largest biotechnology grant ever awarded in Portugal and one of the largest ever approved by AICEP for commercial applications. The grant provides funding to explore utilization of waste streams from fermentation to develop new products and applications while also advancing Amyris's artificial intelligence (AI) and Informatics platform.
     
  • Signed production contract with its contract manufacturer, Antibióticos de León (ADL Biopharma; MAB:ADL), to expand its existing production contract due to demand.
     
  • Successfully launched Biossance brand in Brazil with sales doubling expectations within first 6 weeks.
     
  • Biossance™ brand executing significant expansion with agreement to launch across all 668 Sephora Inside JCPenney Stores, increasing the store count for Biossance purchases from 140 to over 800 locations in the Americas.
     
  • Promoted Caroline Hadfield to President of Biossance in recognition of her leading role in Biossance's success and appointed Catherine Gore as Senior Vice President, Sales, Marketing & Education. Both appointments are expected to accelerate the company's growth in the clean beauty industry, as well as expand Biossance's reach, both internationally and online.
     
  • Secured non-dilutive $36 million term loan to pay off Stegodon and other short-term debt maturities enabling Amyris to resolve its near-term debt maturities. The term loan also includes an additional $35 million accordion credit facility that provides Amyris with another option for financing construction of its production facility(ies), if necessary. The company now has no other significant debt issues to resolve through the rest of the year.

Financial Performance (preliminary unaudited)

Second Quarter 2018

  • GAAP revenue for the second quarter of 2018 was $24.8 million, compared with $25.7 million for the second quarter of 2017. Grants and collaborations revenue was $11.4 million for the second quarter of 2018 compared with $10.3 million for the year-ago period. Second-quarter revenue of $24.8 million compared with the same period in 2017 of $21.7 million when adjusted for the low margin product sales on contracts assigned to DSM. This reflects 15% growth on an absolute basis.
     
  • Sales, general and administrative expenses were $20.2 million for the second quarter of 2018 compared with $15.9 million for year-ago period, primarily reflecting continued investment in our fastest growing and most profitable business activity – Biossance and our natural sweetener business. Research and development expenses of $15.3 million for the quarter were up from $14.2 million for second-quarter 2017 due to increases in headcount to support new partner collaborations.
     
  • GAAP net income attributable to Amyris common stockholders for the second quarter of 2018 reflected significantly improved profitability from operations and was $2.6 million, or $0.05 per basic and $(0.32) per diluted share, compared with a GAAP net loss attributable to Amyris common stockholders for the second quarter of 2017 of $10.3 million, or $0.44 per basic and diluted share. 
     
  • Non-GAAP net loss for the second quarter of 2018 was $21.1 million, or $0.38 per basic and diluted share. This excluded loss from change in fair value of derivative instruments, stock-based compensation expense and cumulative dividends on preferred stock. This compared with a non-GAAP net loss of $30.5 million, or $1.32 per basic and diluted share for the second quarter of 2017.

First Half 2018

  • GAAP revenue for the first half of 2018 was $47.8 million, compared with $38.7 million for 2017. Second-half 2018 revenue of $47.8 million compared with the same period in 2017 of $32.3 million when adjusted for the low margin product sales on contracts assigned to DSM. This reflects 48% growth on an absolute basis.
     
  • GAAP net loss attributable to Amyris common stockholders for the first half of fiscal year 2018 was $89.1 million, or $1.68 per basic and diluted share. Included were several large non-cash items, including loss from extinguishment of debt and a non-cash loss from changes in the fair value of derivatives, stock-based compensation expense and depreciation. This compared to a first half fiscal year 2017 net loss of $47.6 million, or $2.24 per basic and diluted share. Non-GAAP net loss for the first half of fiscal year 2018, excluding the non-cash items mentioned, was $47.5 million, or $0.89 per basic and diluted share, compared to a non-GAAP net loss for the first half of 2017 of $68.7 million, or $3.23 per basic and diluted share.

FINANCIAL RESULTS AND NON-GAAP INFORMATION

To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results. These non-GAAP measures are among the factors management uses in planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Amyris's historical performance as well as comparisons to the operating results of other companies. Management believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management to understand, manage, and evaluate our business and make operating decisions. Our non-GAAP financial measures include the following:

Non-GAAP net income/(loss) calculated as GAAP net income/loss excluding stock-based compensation expense, gain on divestitures, gains and losses from changes in the fair value of derivatives, debt extinguishment costs, depreciation, as well as tangible asset impairments.

Non-GAAP adjusted gross profit (loss) is calculated as cost of product sold and excludes other costs and provisions, Excess Capacity and depreciation and amortization.

Non-GAAP financial information is not prepared under a comprehensive set of accounting rules, and therefore, should only be read in conjunction with financial information reported under U.S. GAAP in order to understand Amyris's operating performance. A reconciliation of the non-GAAP financial measures presented in this release, including non-GAAP net income/(loss), to the most directly comparable GAAP financial measure, is provided in the tables attached to this press release.

QUARTERLY CONFERENCE CALL TODAY

Amyris will discuss these results and provide a business update in a conference call scheduled for 4:30 p.m. ET (1:30 p.m. PT) today. Investors may access the call by dialing (866) 516-3867, participant passcode: 3854857.

A live audio webcast of this conference call and accompanying presentation is also available by visiting the investor relations section of the company's website at http://investors.amyris.com. A replay of the webcast will be available at the investor relations section of the company's website approximately two hours after the conclusion of the call.

About Amyris
Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as the expected closing of significant partnerships in the second half of 2018, anticipated business growth in the second half of 2018, expected future sales and shipments of Amyris's sweetener product, including the anticipated announcement of customers thereof, and expected business and financial results for 2018. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo, Biossance and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners.

Contact:

Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com

-Financial Tables Attached-

       
Amyris, Inc.       
Condensed Consolidated Balance Sheets      
       
(In thousands) June 30, 2018   December 31, 2017
       
Assets      
Current assets:      
Cash and cash equivalents $ 14,050     $ 57,059  
Restricted cash   1,846       2,994  
Short-term investments   130       -  
Accounts receivable, net   26,252       24,281  
Unbilled receivable   14,876       9,340  
Inventories   6,632       5,408  
Prepaid expenses and other current assets   4,687       5,525  
Total current assets   68,473       104,607  
Property, plant and equipment, net   15,300       13,892  
Unbilled receivable, noncurrent   7,980       7,940  
Restricted cash, noncurrent   959       959  
Recoverable taxes from Brazilian government entities   1,057       1,445  
Other assets   24,748       22,640  
Total assets $ 118,517     $ 151,483  
       
Liabilities, mezzanine equity and stockholders' deficit      
Current liabilities:      
Accounts payable $ 19,206     $ 15,921  
Accrued and other current liabilities   20,101       29,402  
Deferred revenue   7,891       4,880  
Debt, current portion   59,987       36,924  
Related party debt, current portion   49,669       20,019  
Total current liabilities   156,854       107,146  
Long-term debt, net of current portion   43,642       61,893  
Related party debt, net of current portion   18,104       46,541  
Derivative liabilities   138,695       119,978  
Other noncurrent liabilities   8,581       10,632  
Total liabilities   365,876       346,190  
       
Mezzanine equity:      
Contingently redeemable common stock   5,000       5,000  
       
Amyris, Inc. stockholders' deficit   (253,296 )     (200,644 )
Noncontrolling interest   937       937  
Total stockholders' deficit   (252,359 )     (199,707 )
Total liabilities, mezzanine equity and stockholders' deficit $ 118,517     $ 151,483  
       
       
       
Unaudited Financial Statements
 

 

               
Amyris, Inc.               
Condensed Consolidated Statements of Operations              
  Three Months Ended
June 30,
  Six Months Ended
June 30,
(In thousands, except per share data) 2018   2017   2018   2017
Revenue              
Renewable products (includes related party revenue of $144, $0, $295 and $0, respectively) $ 6,633     $ 9,892     $ 11,828     $ 17,929  
Licenses and royalties (includes related party revenue of $6,848, $0, $18,248 and $0, respectively) 1   6,774       5,497       18,211       5,752  
Grants and collaborations (includes related party revenue of $1,785, $149, $3,175 and $149, respectively)   11,404       10,290       17,770       14,979  
Total revenue (includes related party revenue of $8,777, $149, $21,718 and $149, respectively)   24,811       25,679       47,809       38,660  
Cost and operating expenses              
Cost of products sold   5,984       17,279       11,299       30,047  
Research and development (2)   15,287       14,249       34,100       28,956  
Sales, general and administrative (2)   20,189       15,949       38,946       28,799  
Total cost and operating expenses   41,460       47,477       84,345       87,802  
Loss from operations   (16,649 )     (21,798 )     (36,536 )     (49,142 )
Other income (expense):              
Interest expense   (8,824 )     (9,303 )     (17,029 )     (21,486 )
Gain (loss) from change in fair value of derivative instruments (3)   24,365       35,775       (39,548 )     38,114  
Gain upon extinguishment of derivative liability   1,857       -       1,857       -  
Gain (loss) upon extinguishment of debt   (26 )     (3,624 )     (26 )     (3,528 )
Other income (expense), net   2,427       (120 )     2,936       (440 )
Total other income (expense)   19,799       22,728       (51,810 )     12,660  
Income (loss) before income taxes   3,150       930       (88,346 )     (36,482 )
Provision for income taxes   -       (310 )     -       (269 )
Net income (loss) attributable to Amyris, Inc.   3,150       620       (88,346 )     (36,751 )
Less deemed dividend on capital distribution to related parties   -       (8,648 )     -       (8,648 )
Less deemed dividend related to beneficial conversion feature on Series A preferred stock   -       (562 )     -       (562 )
Less cumulative dividends on Series A and Series B preferred stock   (399 )     (1,675 )     (794 )     (1,675 )
Less earnings allocated to participating securities   (163 )     -       -       -  
Net income (loss) attributable to Amyris, Inc. common stockholders $ 2,588     $ (10,265 )   $ (89,140 )   $ (47,636 )
               
Net income (loss) per share attributable to common stockholders, basic (4) $ 0.05     $ (0.44 )   $ (1.68 )   $ (2.24 )
Net income (loss) per share attributable to common stockholders, diluted (4) $ (0.32 )   $ (0.44 )   $ (1.68 )   $ (2.24 )
               
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic   54,932,411       23,155,874       53,076,975       21,226,013  
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted   60,907,809       23,155,874       53,076,975       21,226,013  
               
(1) Value share revenue has been reclassified to licenses and royalties revenue from renewable products revenue to better reflect the company's current business model and to provide more transparency as that portion of overall revenue grows. Prior-year amounts have been reclassified to conform to this presentation.
               
  Three Months Ended
June 30,
  Six Months Ended
June 30,
(2) Includes stock-based compensation expense as follows: 2018   2017   2018   2017
Research and development $ 333     $ 441     $ 696     $ 925  
Sales, general and administrative   1,567       597       2,482       1,759  
  $ 1,900     $ 1,038     $ 3,178     $ 2,684  
               
(3) Upon remeasuring the fair value of its derivative liabilities, the Company recorded non-cash gains for the three months ended June 30, 2018 and the three and six months ended June 30, 2017, and a non-cash loss for the six months ended June 30, 2018. Changes in the fair value of derivative liabilities are primarily the result of changes in Amyris's stock price during each of the periods presented. The gains and losses for all periods presented include the change in fair value of derivatives in connection with certain features of outstanding convertible notes and warrants, related to change in control protection and price-based anti-dilution adjustment provisions.

(4) The Company is reviewing its calculations of net loss per share for the three and six months ended June 30, 2018, which will be finalized in the 10-Q to be filed subsequent to this release.
               
Amyris, Inc.               
Reconciliation of GAAP to Non-GAAP Financial Information              
  Three Months Ended
June 30,
  Six Months Ended
June 30,
(In thousands, except per share data) 2018   2017   2018   2017
Net income (loss) attributable to Amyris, Inc. common stockholders (GAAP) $ 2,588     $ (10,265 )   $ (89,140 )   $ (47,636 )
Non-GAAP adjustments:              
Stock-based compensation expense   1,900       1,038       3,178       2,684  
(Gain) loss from change in fair value of derivative instruments(2)   (24,365 )     (35,775 )     39,548       (38,114 )
Gain upon extinguishment of derivative liability   (1,857 )     -       (1,857 )     -  
Loss upon extinguishment of debt   26       3,624       26       3,528  
Deemed dividend on capital distribution to related parties   -       8,648       -       8,648  
Deemed dividend related to beneficial conversion feature on Series A preferred stock   -       562       -       562  
Cumulative dividends on Series A and Series B preferred stock   399       1,675       794       1,675  
Earnings allocated to participating securities   163       -       -       -  
Net loss attributable to Amyris, Inc. common stockholders (non-GAAP) $    (21,146 )   $    (30,493 )   $    (47,451 )   $    (68,653 )
               
Weighted-average shares outstanding              
Shares outstanding, basic   54,932,411       23,155,874       53,076,975       21,226,013  
               
Net income (loss) per share attributable to Amyris, Inc. common stockholders - Basic (GAAP)(3) $ 0.05     $ (0.44 )   $ (1.68 )   $ (2.24 )
Non-GAAP adjustments:              
Stock-based compensation expense   0.03       0.04       0.06       0.13  
(Gain) loss from change in fair value of derivative instruments(2)   (0.44 )     (1.54 )     0.75       (1.81 )
Gain upon extinguishment of derivative liability   (0.03 )     -       (0.03 )     -  
Loss upon extinguishment of debt   -       0.16       -       0.17  
Deemed dividend on capital distribution to related parties   -       0.37       -       0.41  
Deemed dividend related to beneficial conversion feature on Series A preferred stock   -       0.02       -       0.03  
Cumulative dividends on Series A and Series B preferred stock   0.01       0.07       0.01       0.08  
Earnings allocated to participating securities   -       -       -       -  
Net loss per share attributable to Amyris, Inc. common stockholders - Basic (non-GAAP) $    (0.38 )   $    (1.32 )   $    (0.89 )   $    (3.23 )
               
Unaudited Financial Statements
               


               
Amyris, Inc.               
Reconciliation of GAAP to Non-GAAP Financial Information              
  Three Months Ended
June 30,
  Six Months Ended
June 30,
(In thousands) 2018   2017   2018   2017
Revenue (GAAP and non-GAAP)              
Renewable products $ 6,633     $ 9,892     $ 11,828     $ 17,929  
Licenses and royalties   6,774       5,497       18,211       5,752  
Grants and collaborations   11,404       10,290       17,770       14,979  
Total revenue (GAAP and non-GAAP) $    24,811     $    25,679     $    47,809     $    38,660  
               
Cost of products sold (GAAP) $ 5,984     $ 17,279     $ 11,299     $ 30,047  
Other costs/provisions   (1,527 )     1,966       (2,246 )     4,603  
Excess capacity   (472 )     (629 )     (977 )     (1,549 )
Depreciation and amortization   (99 )     (911 )     (191 )     (1,842 )
Cost of products sold (non-GAAP) $    3,886     $    17,705     $    7,885     $    31,259  
               
Adjusted gross profit (non-GAAP)(1) $    20,925     $    7,974     $    39,924     $    7,401  
Gross margin (%)   84.3 %     31.1 %     83.5 %     19.1 %
               
Research and development expense (GAAP) $ 15,287     $ 14,249     $ 34,100     $ 28,956  
Stock-based compensation expense   (333 )     (441 )     (696 )     (925 )
Depreciation and amortization   (1,090 )     (1,600 )     (2,365 )     (3,201 )
Research and development expense (non-GAAP) $    13,864     $    12,208     $    31,039     $    24,830  
               
Sales, general and administrative expense (GAAP) $ 20,189     $ 15,949     $ 38,946     $ 28,799  
Stock-based compensation expense   (1,567 )     (597 )     (2,482 )     (1,759 )
Depreciation and amortization   (194 )     (179 )     (388 )     (387 )
Sales, general and administrative expense (non-GAAP) $    18,428     $    15,173     $    36,076     $    26,653  
               
(1) Non-GAAP Adjusted Gross Profit is calculated based on non-GAAP adjustments to cost of products sold, and does not include costs related to collaborations.
               
               
Unaudited Financial Information
 

 

Primary Logo

View Comments and Join the Discussion!